These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33667419)

  • 1. Computational model of cardiomyocyte apoptosis identifies mechanisms of tyrosine kinase inhibitor-induced cardiotoxicity.
    Grabowska ME; Chun B; Moya R; Saucerman JJ
    J Mol Cell Cardiol; 2021 Jun; 155():66-77. PubMed ID: 33667419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies.
    Singh AP; Glennon MS; Umbarkar P; Gupte M; Galindo CL; Zhang Q; Force T; Becker JR; Lal H
    Cardiovasc Res; 2019 Apr; 115(5):966-977. PubMed ID: 30629146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three tyrosine kinase inhibitors cause cardiotoxicity by inducing endoplasmic reticulum stress and inflammation in cardiomyocytes.
    Wang H; Wang Y; Li J; He Z; Boswell SA; Chung M; You F; Han S
    BMC Med; 2023 Apr; 21(1):147. PubMed ID: 37069550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity.
    Cheng H; Kari G; Dicker AP; Rodeck U; Koch WJ; Force T
    Circ Res; 2011 Dec; 109(12):1401-9. PubMed ID: 21998323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adaptation of Human iPSC-Derived Cardiomyocytes to Tyrosine Kinase Inhibitors Reduces Acute Cardiotoxicity via Metabolic Reprogramming.
    Wang H; Sheehan RP; Palmer AC; Everley RA; Boswell SA; Ron-Harel N; Ringel AE; Holton KM; Jacobson CA; Erickson AR; Maliszewski L; Haigis MC; Sorger PK
    Cell Syst; 2019 May; 8(5):412-426.e7. PubMed ID: 31078528
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentraxin 3 regulates tyrosine kinase inhibitor-associated cardiomyocyte contraction and mitochondrial dysfunction via ERK/JNK signalling pathways.
    Chen YT; Masbuchin AN; Fang YH; Hsu LW; Wu SN; Yen CJ; Liu YW; Hsiao YW; Wang JM; Rohman MS; Liu PY
    Biomed Pharmacother; 2023 Jan; 157():113962. PubMed ID: 36370523
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systems pharmacological analysis of mitochondrial cardiotoxicity induced by selected tyrosine kinase inhibitors.
    Vaidya T; Kamta J; Chaar M; Ande A; Ait-Oudhia S
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):401-418. PubMed ID: 29446053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Kinome and Transcriptome Profiling Reveal Broad and Distinct Activities of Erlotinib, Sunitinib, and Sorafenib in the Mouse Heart and Suggest Cardiotoxicity From Combined Signal Transducer and Activator of Transcription and Epidermal Growth Factor Receptor Inhibition.
    Stuhlmiller TJ; Zawistowski JS; Chen X; Sciaky N; Angus SP; Hicks ST; Parry TL; Huang W; Beak JY; Willis MS; Johnson GL; Jensen BC
    J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 29051215
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular mechanisms of cardiotoxicity of gefitinib in vivo and in vitro rat cardiomyocyte: Role of apoptosis and oxidative stress.
    Korashy HM; Attafi IM; Ansari MA; Assiri MA; Belali OM; Ahmad SF; Al-Alallah IA; Anazi FE; Alhaider AA
    Toxicol Lett; 2016 Jun; 252():50-61. PubMed ID: 27084042
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Multi-parameter in vitro toxicity testing of crizotinib, sunitinib, erlotinib, and nilotinib in human cardiomyocytes.
    Doherty KR; Wappel RL; Talbert DR; Trusk PB; Moran DM; Kramer JW; Brown AM; Shell SA; Bacus S
    Toxicol Appl Pharmacol; 2013 Oct; 272(1):245-55. PubMed ID: 23707608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dietary phytoestrogens present in soy dramatically increase cardiotoxicity in male mice receiving a chemotherapeutic tyrosine kinase inhibitor.
    Harvey PA; Leinwand LA
    Mol Cell Endocrinol; 2015 Jan; 399():330-5. PubMed ID: 25458703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intracellular Signaling Pathways Mediating Tyrosine Kinase Inhibitor Cardiotoxicity.
    Scott SS; Greenlee AN; Matzko A; Stein M; Naughton MT; Zaramo TZ; Schwendeman EJ; Mohammad SJ; Diallo M; Revan R; Shimmin G; Tarun S; Ferrall J; Ho TH; Smith SA
    Heart Fail Clin; 2022 Jul; 18(3):425-442. PubMed ID: 35718417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cyclin-dependent kinase 2 protects against doxorubicin-induced cardiomyocyte apoptosis and cardiomyopathy.
    Xia P; Liu Y; Chen J; Coates S; Liu DX; Cheng Z
    J Biol Chem; 2018 Dec; 293(51):19672-19685. PubMed ID: 30361442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update of the molecular mechanisms underlying doxorubicin plus trastuzumab induced cardiotoxicity.
    Anjos M; Fontes-Oliveira M; Costa VM; Santos M; Ferreira R
    Life Sci; 2021 Sep; 280():119760. PubMed ID: 34166713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiotoxicity of sorafenib is mediated through elevation of ROS level and CaMKII activity and dysregulation of calcium homoeostasis.
    Ma W; Liu M; Liang F; Zhao L; Gao C; Jiang X; Zhang X; Zhan H; Hu H; Zhao Z
    Basic Clin Pharmacol Toxicol; 2020 Feb; 126(2):166-180. PubMed ID: 31483925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells.
    Sharma A; Burridge PW; McKeithan WL; Serrano R; Shukla P; Sayed N; Churko JM; Kitani T; Wu H; Holmström A; Matsa E; Zhang Y; Kumar A; Fan AC; Del Álamo JC; Wu SM; Moslehi JJ; Mercola M; Wu JC
    Sci Transl Med; 2017 Feb; 9(377):. PubMed ID: 28202772
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Downregulation of stanniocalcin 1 is responsible for sorafenib-induced cardiotoxicity.
    Kawabata M; Umemoto N; Shimada Y; Nishimura Y; Zhang B; Kuroyanagi J; Miyabe M; Tanaka T
    Toxicol Sci; 2015 Feb; 143(2):374-84. PubMed ID: 25370841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib.
    Singh AP; Umbarkar P; Tousif S; Lal H
    Int J Cardiol; 2020 Oct; 316():214-221. PubMed ID: 32470534
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impaired autophagy and mitochondrial dynamics are involved in Sorafenib-induced cardiomyocyte apoptosis.
    Liang F; Zhang K; Ma W; Zhan H; Sun Q; Xie L; Zhao Z
    Toxicology; 2022 Nov; 481():153348. PubMed ID: 36209947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mitochondrial Toxicity Associated with Imatinib and Sorafenib in Isolated Rat Heart Fibers and the Cardiomyoblast H9c2 Cell Line.
    Bouitbir J; Panajatovic MV; Krähenbühl S
    Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.